UBS Maintains Neutral on Chemours, Lowers Price Target to $15
Benzinga Newsdesk 4 hours ago
Analyst RatingsNewsPrice Target
UBS analyst Joshua Spector maintains Chemours (NYSE:CC) with a Neutral and lowers the price target from $16 to $15.
UBS analyst Joshua Spector maintains Chemours (NYSE:CC) with a Neutral and lowers the price target from $16 to $15.